PD-Rx Pharmaceuticals, Inc (PDRX) Fair Value & Analysis

Healthcare · US · Market cap $5.7M

A solid business, screening 180% undervalued on our models.

What matters now

• The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict.
• The price is below even our cautious bear case ($7.64). The market is more pessimistic than our downside scenario.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.

How to read this chart

60‑month range $2.00 – $7.20 · fair‑value band $7.64 – $11.11 · the $3.35 price screens below the $9.38 fair value. Dashed = 300-day average. As of Jul 25, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PD-Rx Pharmaceuticals, Inc (PDRX) currently trades at $3.35, while our model-based Fair Value estimate is $9.38, implying the stock looks roughly 180.0% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, PD-Rx Pharmaceuticals, Inc generated revenue of $18.3M at a net margin of -1.4%. Revenue declined 2.5% year over year. It earns a return on equity of -2.5%. The balance sheet holds a net cash position of $6.2M. Fundamentals as of Jul 25, 2026

Our scenario range runs from $7.64 (bear case) to $11.11 (bull case); at $3.35, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 39% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 180%, PDRX screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Dividend Discount ($16.38) versus Asset-Based ($4.00). Highest evidence: Growth DCF (72).

Key figures & financial health

Quality Score breakdown

About the company

PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services.

Full company description

PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a handling package; and PD-Rx Net, a web-based application designed to track prescriptions filled at the point of care and print prescription labels for prescriptions that are filled onsite. Further, it provides primary care, urgent care, pain management, occupational and orthopedic medicine, bariatric, dental, and other physician dispensing services. The company serves the governmental, commercial, and point-of-care pharmaceutical industry. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is based in Oklahoma City, Oklahoma.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PD-Rx Pharmaceuticals, Inc reported revenue of $18.3M in FY2025 versus $21.6M in FY2021, a compound −4.0%/yr. Reported net income was −$258K in FY2025.

Watch PDRX: get an alert when its fair value changes →

Peer Group

Medical Distribution · 81 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Distribution median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.